Editas Medicine (EDIT) Non Operating Income (2015 - 2025)
Editas Medicine (EDIT) posted quarterly Non Operating Income of -$569000.0 for Q3 2025, down 116.14% year-over-year from $3.5 million in Q3 2024, and up 66.35% quarter-over-quarter from -$1.7 million in Q2 2025.
Editas Medicine (EDIT) Non Operating Income (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Non Operating Income for 11 consecutive years, with -$569000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Non Operating Income fell 116.14% year-over-year to -$569000.0; the TTM figure through Sep 2025 stood at -$987000.0 (down 105.5% YoY), while the FY2024 annual figure was $14.1 million, down 11.92% from the prior year.
- Non Operating Income improved to -$569000.0 in Q3 2025 per EDIT's latest filing, from -$1.7 million in the prior quarter.
- Across five years, Non Operating Income topped out at $5.1 million in Q3 2023 and bottomed at -$1.7 million in Q2 2025.
- Historically, Non Operating Income has averaged $1.8 million across 5 years, with a median of $1.2 million in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Income jumped 1456.32% — and 2025, when it tumbled 139.36%.
- Editas Medicine's Non Operating Income stood at $174000.0 in 2021, then surged by 1456.32% to $2.7 million in 2022, then soared by 87.89% to $5.1 million in 2023, then plunged by 76.45% to $1.2 million in 2024, then sank by 147.5% to -$569000.0 in 2025.
- Business Quant data shows EDIT's Non Operating Income at -$569000.0 in Q3 2025, -$1.7 million in Q2 2025, and $75000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Editas Medicine | 263.01 Mn | 116.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -569,000.00 |
| Jun 30, 2025 | -1.69 Mn |
| Mar 31, 2025 | 75,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | 3.53 Mn |
| Jun 30, 2024 | 4.30 Mn |
| Mar 31, 2024 | 5.04 Mn |
| Dec 31, 2023 | 5.09 Mn |
| Sep 30, 2023 | 5.14 Mn |
| Jun 30, 2023 | 3.80 Mn |
| Mar 31, 2023 | 1.93 Mn |
| Dec 31, 2022 | 2.71 Mn |
| Sep 30, 2022 | 1.79 Mn |
| Jun 30, 2022 | 781,000.00 |
| Mar 31, 2022 | 235,000.00 |
| Dec 31, 2021 | 174,000.00 |
| Sep 30, 2021 | 171,000.00 |
| Jun 30, 2021 | 145,000.00 |
| Mar 31, 2021 | 155,000.00 |
| Dec 31, 2020 | 3.38 Mn |